Distinguishing Between Thymic Carcinoma and Lung Carcinoma: a Medical Oncologist's Perspective

Overview

Journal Mediastinum

Publisher AME Publishing Company

Date 2022 Sep 27

PMID 36164359

Authors

Arun Rajan

Cristina Mullenix

Meredith J McAdams

Affiliations

Soon will be listed here.

References

Ballman M, Zhao C, McAdams M, Rajan A . Immunotherapy for Management of Thymic Epithelial Tumors: A Double-Edged Sword. Cancers (Basel). 2022; 14(9). PMC: 9105984. DOI: 10.3390/cancers14092060. View

Benitez J, Boucher M, Dansin E, Kerjouan M, Bigay-Game L, Pichon E . Central Nervous System Metastases in Thymic Epithelial Tumors: A Brief Report of Real-World Insight From RYTHMIC. J Thorac Oncol. 2021; 16(12):2144-2149. DOI: 10.1016/j.jtho.2021.08.008. View

DAntonio C, Passaro A, Gori B, Del Signore E, Migliorino M, Ricciardi S . Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol. 2014; 6(3):101-14. PMC: 3987652. DOI: 10.1177/1758834014521110. View

Kitadai R, Okuma Y . Future Perspective of Chemotherapy and Pharmacotherapy in Thymic Carcinoma. Cancers (Basel). 2021; 13(20). PMC: 8533972. DOI: 10.3390/cancers13205239. View

Simeone J, Nordstrom B, Patel K, Klein A . Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting. Future Oncol. 2019; 15(30):3491-3502. DOI: 10.2217/fon-2019-0348. View

Mammen A, Rajan A, Pak K, Lehky T, Casciola-Rosen L, Donahue R . Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. Ann Rheum Dis. 2018; 78(1):150-152. PMC: 6447048. DOI: 10.1136/annrheumdis-2018-213777. View

Khandelwal A, Sholl L, Araki T, Ramaiya N, Hatabu H, Nishino M . Patterns of metastasis and recurrence in thymic epithelial tumours: longitudinal imaging review in correlation with histological subtypes. Clin Radiol. 2016; 71(10):1010-1017. PMC: 5010483. DOI: 10.1016/j.crad.2016.05.007. View

Fenske D, Price G, Hess L, John W, Kim E . Systematic Review of Brain Metastases in Patients With Non-Small-Cell Lung Cancer in the United States, European Union, and Japan. Clin Lung Cancer. 2017; 18(6):607-614. DOI: 10.1016/j.cllc.2017.04.011. View

Padda S, Yao X, Antonicelli A, Riess J, Shang Y, Shrager J . Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database. J Thorac Oncol. 2017; 13(3):436-446. PMC: 5983900. DOI: 10.1016/j.jtho.2017.11.118. View

10.

Roden A, Szolkowska M . Common and rare carcinomas of the thymus. Virchows Arch. 2021; 478(1):111-128. DOI: 10.1007/s00428-020-03000-6. View

11.

Kanaji N, Watanabe N, Kita N, Bandoh S, Tadokoro A, Ishii T . Paraneoplastic syndromes associated with lung cancer. World J Clin Oncol. 2014; 5(3):197-223. PMC: 4127595. DOI: 10.5306/wjco.v5.i3.197. View

12.

Miret M, Horvath-Puho E, Deruaz-Luyet A, Sorensen H, Ehrenstein V . Potential paraneoplastic syndromes and selected autoimmune conditions in patients with non-small cell lung cancer and small cell lung cancer: A population-based cohort study. PLoS One. 2017; 12(8):e0181564. PMC: 5540596. DOI: 10.1371/journal.pone.0181564. View

13.

Honda O, Johkoh T, Sekiguchi J, Tomiyama N, Mihara N, Sumikawa H . Doubling time of lung cancer determined using three-dimensional volumetric software: comparison of squamous cell carcinoma and adenocarcinoma. Lung Cancer. 2009; 66(2):211-7. DOI: 10.1016/j.lungcan.2009.01.018. View

14.

Giaccone G, Kim C . Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up. J Thorac Oncol. 2020; 16(3):483-485. DOI: 10.1016/j.jtho.2020.11.003. View

15.

Thai A, Solomon B, Sequist L, Gainor J, Heist R . Lung cancer. Lancet. 2021; 398(10299):535-554. DOI: 10.1016/S0140-6736(21)00312-3. View

16.

Radovich M, Pickering C, Felau I, Ha G, Zhang H, Jo H . The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell. 2018; 33(2):244-258.e10. PMC: 5994906. DOI: 10.1016/j.ccell.2018.01.003. View

17.

Schirosi L, Nannini N, Nicoli D, Cavazza A, Valli R, Buti S . Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. Ann Oncol. 2012; 23(9):2409-2414. DOI: 10.1093/annonc/mdr626. View

18.

Fukumoto K, Fukui T, Kawaguchi K, Nakamura S, Hakiri S, Ozeki N . The tumor doubling time is a useful parameter for predicting the histological type of thymic epithelial tumors. Surg Today. 2019; 49(8):656-660. DOI: 10.1007/s00595-019-01822-9. View